59 Papers
85 Citations
Fankai Meng is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 30 publications.
Chat about Author
Papers
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Yang Cao,Jia Wei,Liang Zou,Tiebin Jiang,Gaoxiang Wang,Liting Chen,Liang Huang,Fankai Meng,Lifang Huang,Na Wang,Xiaoxi Zhou,Hui Luo,Zekai Mao,Xing Chen,Jungang Xie,Jing Liu,Hui Cheng,Jianping Zhao,Gang Huang,Wei Wang,Jianfeng Zhou +20 more
TL;DR: Treatment with ruxolitinib plus SoC was not associated with significantly accelerated clinical improvement in severe patients with COVID-19, although ruxolinib recipients had a numerically faster clinical improvement.
475
Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling.
TL;DR: It is demonstrated that autoactivated Shh signaling provides survival and proliferative cues in C ML progenitor cells through downstream β-catenin signaling, suggesting a novel therapeutic approach in CML.
46
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
Jia-Ying Wu,Fankai Meng,Yang Cao,Yicheng Zhang,Xiaojian Zhu,Na Wang,Jue Wang,Lifang Huang,Jianfeng Zhou,Yi Xiao +9 more
TL;DR: In this article, the authors treated 13 central nervous system lymphoma (CNSL) patients with ASCT sequential CD19/22 CAR T-cell infusion and simultaneously evaluated the clinical efficacy and toxicity.
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
Jia Wei,Ming Xiao,Zekai Mao,Nan Wang,Yang Cao,Yi Xiao,Fankai Meng,Weimin Sun,Ying Wang,Xingcheng Yang,Liting Chen,Yichen Zhang,Haichuan Zhu,Shangkun Zhang,Tong-Cun Zhang,Jian Feng Zhou,Liang Huang +16 more
TL;DR: In this article , CAR19/22 T-cell treatment in combination with ASCT resulted in higher ORR, CRR, PFS, and OS, but reduced occurrence of severe CRS in this patient population.
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain.
Tongjuan Li,Lei Zhao,Yuanyuan Zhang,Yi Xiao,Di Wang,Liang Huang,Liya Ma,Liting Chen,Songya Liu,Xiaolu Long,Fankai Meng,Xiaojian Zhu,Jia Wei,Bin Xu,Jianfeng Zhou,Xiaoxi Zhou +15 more
TL;DR: The study indicates the efficacy of CAR T-cell therapy for CNS lymphoma with an acceptable safety profile; however, the remission did not last long, perhaps due to the tumor immunosuppressive microenvironment (TME) of the CNS.